statins

LAPLACE 2: Evolocumab effective in reducing LDL associated with statins

There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that inhibits protein converting subtilisin / kexin type 9 (PCSK9) showed lowering LDL cholesterol in phase 2 studies. The objective of this Phase 3 study was to evaluate the safety and efficacy...

IVUS plaque regression with high doses of statins

Original title: Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Reference: Räber L et al. Eur Heart J. 2015 Feb 21;36(8):490-500. The long-term effect of intensive statin therapy on coronary atherosclerosis in patients admitted pursuing an ST segment elevation myocardial infarction is unknown. The aim of this study was...

High doses of statins may reduce the lipid content in severe injury

Original title: Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy. The YELLOW Trial (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy). Reference: Annapoorna S. Kini et al. J Am Coll Cardiol 2013;62:21–9. Multiple studies have shown the benefits of statins in reducing all events, stabilize plaques and improve endothelial function. Coronary intravascular ultrasound (IVUS)...

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

MITRAL Trial, Results at 5 Years

Repeat mitral valve repair has been associated with increased mortality. Transcatheter mitral valve repair has surged as an alternative for patients treated with mitral valve-in-valve (MViV), valve-in-ring (MViR), or valve-in-mitral for annular calcification (ViMAC). Current data from the VIVID and the MAC Global Registry on 30-day evolution in these 3 scenarios show 7.4%, 11.4% and...

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

TriClip: Good Outcomes After a 2-Year Follow-up

Severe tricuspid regurgitation (TR) is an underestimated condition in healthcare systems. However, it is more common than believed, especially in individuals over 65 years of age.  This condition is linked to hospitalizations due to heart failure, mortality rates, and a progressive decline in quality of life.  Surgery to treat TR on its own is complicated,...

Top